These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 9111295

  • 1. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.
    Arttamangkul S, Ishmael JE, Murray TF, Grandy DK, DeLander GE, Kieffer BL, Aldrich JV.
    J Med Chem; 1997 Apr 11; 40(8):1211-8. PubMed ID: 9111295
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
    Vig BS, Murray TF, Aldrich JV.
    J Med Chem; 2004 Jan 15; 47(2):446-55. PubMed ID: 14711314
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2.
    Lung FD, Collins N, Stropova D, Davis P, Yamamura HI, Porreca F, Hruby VJ.
    J Med Chem; 1996 Mar 01; 39(5):1136-41. PubMed ID: 8676350
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 1. Conformational constraint in the "message" sequence.
    Arttamangkul S, Murray TF, DeLander GE, Aldrich JV.
    J Med Chem; 1995 Jun 23; 38(13):2410-7. PubMed ID: 7608905
    [Abstract] [Full Text] [Related]

  • 5. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
    Vig BS, Zheng MQ, Murray TF, Aldrich JV.
    J Med Chem; 2003 Sep 11; 46(19):4002-8. PubMed ID: 12954053
    [Abstract] [Full Text] [Related]

  • 6. Development of highly potent and selective dynorphin A analogues as new medicines.
    Lung FD, Chen CH, Liu JH.
    J Pept Res; 2005 Nov 11; 66(5):263-76. PubMed ID: 16218994
    [Abstract] [Full Text] [Related]

  • 7. Dynorphin A analogs containing a conformationally constrained phenylalanine derivative in position 4: reversal of preferred stereochemistry for opioid receptor affinity and discrimination of kappa vs. delta receptors.
    Aldrich JV, Zheng QI, Murray TF.
    Chirality; 2001 Nov 11; 13(3):125-9. PubMed ID: 11270320
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution.
    Choi H, Murray TF, DeLander GE, Schmidt WK, Aldrich JV.
    J Med Chem; 1997 Aug 15; 40(17):2733-9. PubMed ID: 9276018
    [Abstract] [Full Text] [Related]

  • 9. [Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist.
    Patkar KA, Yan X, Murray TF, Aldrich JV.
    J Med Chem; 2005 Jul 14; 48(14):4500-3. PubMed ID: 15999987
    [Abstract] [Full Text] [Related]

  • 10. Prediction of the conformational requirements for binding to the kappa-opioid receptor and its subtypes. I. Novel alpha-helical cyclic peptides and their role in receptor selectivity.
    Collins N, Hruby VJ.
    Biopolymers; 1994 Sep 14; 34(9):1231-41. PubMed ID: 7948735
    [Abstract] [Full Text] [Related]

  • 11. Effects of modifications of residues in position 3 of dynorphin A(1-11)-NH2 on kappa receptor selectivity and potency.
    Lung FD, Meyer JP, Lou BS, Xiang L, Li G, Davis P, DeLeon IA, Yamamura HI, Porreca F, Hruby VJ.
    J Med Chem; 1996 Jun 21; 39(13):2456-60. PubMed ID: 8691442
    [Abstract] [Full Text] [Related]

  • 12. Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
    Kawasaki AM, Knapp RJ, Kramer TH, Walton A, Wire WS, Hashimoto S, Yamamura HI, Porreca F, Burks TF, Hruby VJ.
    J Med Chem; 1993 Mar 19; 36(6):750-7. PubMed ID: 8096246
    [Abstract] [Full Text] [Related]

  • 13. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
    Bennett MA, Murray TF, Aldrich JV.
    J Pept Res; 2005 Mar 19; 65(3):322-32. PubMed ID: 15787962
    [Abstract] [Full Text] [Related]

  • 14. Structure-activity relationships of dynorphin a analogues modified in the address sequence.
    Schlechtingen G, DeHaven RN, Daubert JD, Cassel JA, Chung NN, Schiller PW, Taulane JP, Goodman M.
    J Med Chem; 2003 May 22; 46(11):2104-9. PubMed ID: 12747782
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Design and synthesis of highly potent and selective cyclic dynorphin A analogues.
    Kawasaki AM, Knapp RJ, Kramer TH, Wire WS, Vasquez OS, Yamamura HI, Burks TF, Hruby VJ.
    J Med Chem; 1990 Jul 22; 33(7):1874-9. PubMed ID: 1972964
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Conformationally readdressed CCK-B/delta-opioid peptide ligands.
    Nikiforovich GV, Kolodziej SA, Nock B, Bernad N, Martinez J, Marshall GR.
    Biopolymers; 1995 Oct 22; 36(4):439-52. PubMed ID: 7578939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.